The MedicX Fund Limited Issue of Ordinary Shares (5114S)

TIDMMXF

RNS Number : 5114S

The MedicX Fund Limited

25 June 2018

For immediate release

25 June 2018

MedicX Fund Limited

("MedicX", "the Fund" or "the Company")

Issue of Ordinary Shares

MedicX Fund Limited (the "Company") announces that earlier today, Monday 25 June 2018, it issued for cash 1,000,000 ordinary shares of no par value in the Company. The ordinary shares were issued under the Company's block listing facility, at a price of 81.25 pence per share.

The net proceeds raised will be used by the Company for general commercial purposes.

Total voting rights

In accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, the total number of ordinary shares of the Company in issue following this transaction will be 442,430,576 shares (excluding treasury shares) each with one voting right. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the Disclosure and Transparency Rules.

As at today's date, the Company also holds 3,271,823 ordinary shares in treasury. Following the sale out of treasury of 368,440 ordinary shares in lieu of cash for the June 2018 dividend, payable on 29 June 2018 (as announced on 13 June 2018), the Company is expected to have 2,903,383 ordinary shares held in treasury.

The Company has 5,071,668 ordinary shares of no par value remaining under its block listing facility to be used to satisfy demand that cannot be met through the secondary market.

End

For further information please contact:

   Octopus Healthcare Adviser Limited                                  [phone] 
   Octopus Healthcare Group                                               [phone] 

Mike Adams, Executive Chairman

Buchanan [phone]

Charles Ryland/Henry Wilson

   Canaccord Genuity Limited                                                 [phone] 

Robbie Robertson/Andrew Zychowski/Helen Goldsmith

Liberum [phone]

Richard Crawley/Jamie Richards

Information on MedicX Fund Limited

MedicX Fund Limited ("MXF", "MedicX Fund", the "Fund" or the "Company", or together with its subsidiaries, the "Group") is a specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom and Ireland, listed on the London Stock Exchange, with a portfolio comprising 166 properties.

The Investment Adviser to the Company is Octopus Healthcare Adviser Ltd, which is part of the Octopus Healthcare group. Octopus Healthcare invests in and develops properties as well as creating partnerships to deliver innovative healthcare buildings to improve the health, wealth and wellbeing of the UK. It currently manages over GBP1.4 billion of healthcare investments across a number of platforms, with a focus on five core areas: GP surgeries, care homes, special education schools, retirement housing and private hospitals. Octopus Healthcare is part of the Octopus group, a fast-growing UK fund management business with leading positions in several specialist sectors including healthcare property, energy, property finance and smaller company investing. Octopus manages GBP7.7 billion of funds for more than 50,000 retail and institutional investors as well as supplying energy to more than 180,000 customers.

Octopus Healthcare Adviser Ltd is authorised and regulated by the Financial Conduct Authority.

The Company's website address is www.medicxfund.com. Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website), nor the contents of any website accessible from hyperlinks within this announcement, are incorporated into, or form part of, this announcement.

The Company's Legal Entity Identifier is 2138008POF35FTNFCB25.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

IOESEDFIIFASEEM

(END) Dow Jones Newswires

June 25, 2018 11:27 ET (15:27 GMT)